Rare disease treatment funding in India is currently witnessing a period of significant transition and challenge. Recent government data shows a sharp drop in financial allocations for the 2025-26 period. This funding shift occurs even as several major medical institutions report substantial unspent balances from previous years.

The Current State of Rare Disease Treatment Funding

Official records indicate that allocations for rare diseases fell from Rs 82.87 crore in 2024-25 to Rs 32.73 crore in 2025-26. This reduction primarily affects various Centres of Excellence across the country. Institutions such as AIIMS Delhi and SGPGI Lucknow did not receive new funds because they carried forward existing balances. However, this lack of fresh allocation raises concerns among patient advocates and medical professionals. They worry that administrative delays might hinder access to high-cost therapies for genetic and metabolic disorders.

Identifying Structural Gaps in the NPRD

The National Policy for Rare Diseases supports patients with conditions like Duchenne muscular dystrophy and Pompe disease. However, the current funding structure often leads to perceived inefficiencies. Currently, the government earmarks up to Rs 50 lakh for each individual patient. This specific allocation means that money stays with a patient throughout their treatment cycle. Therefore, funds may appear unspent on institutional ledgers while they are actually committed to long-term care. Furthermore, activists highlight that the processing of new applications remains slow. At AIIMS Delhi, for instance, many applications still await approval despite the available budget.

Implications for Long-Term Patient Care

Experts emphasize that rare disease management requires consistent and timely financial support. Because many of these conditions are lifelong, a single grant may not suffice for permanent care. Doctors must navigate these complex regulatory frameworks to secure the best outcomes for their patients. Consequently, the medical community is calling for a more sustainable and flexible funding mechanism. Such a system would ensure that financial resources translate into immediate clinical benefits without administrative bottlenecks.

Frequently Asked Questions

Q1: Why has the allocation for rare disease treatment funding decreased recently?

Fresh allocations decreased because several Centres of Excellence still hold unspent funds from previous years. The government prioritizes the utilization of existing balances before releasing new grants.

Q2: How does the Rs 50 lakh cap affect patient treatment?

The Rs 50 lakh cap provides significant one-time support for high-cost therapies. However, clinicians often face challenges when patients require lifelong treatment that exceeds this financial limit.

Q3: Which institutions are designated as Centres of Excellence for rare diseases?

Major institutions like AIIMS Delhi, PGIMER Chandigarh, and MAMC serve as Centres of Excellence. These hubs receive funds under the National Policy for Rare Diseases to treat complex genetic conditions.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Rare disease funds drop, unspent money piles up at key centres - ETHealthworld


2. National Policy for Rare Diseases (NPRD), 2021 - Ministry of Health and Family Welfare, Government of India.


3. Implementation Guidelines for Rare Diseases Support - Directorate General of Health Services (DGHS).